HHS will not enforce against 503A compounding of six peptides, under ten conditions
On October 30, 2026 HHS published an interim policy: it does not intend to act against state licensed pharmacies or physicians compounding BPC-157, Epitalon, KPV, MOTS-c, Semax or TB-500, if every condition is met and only in the listed forms and routes.
FDA's Pharmacy Compounding Advisory Committee voted in July 2026 to recommend these six peptides for the 503A bulks list, against the recommendation of FDA's drug center. The Secretary's policy, filed October 28 and published October 30, now says HHS does not intend to take enforcement action against compounding with them until a final rule decides whether each is listed. The notice describes it as a draft interim policy that creates no rights and binds no one.
All ten conditions must be met, including: API from an FDA registered manufacturer with a lot specific certificate of analysis; a single active ingredient; the label "This is a compounded drug product. Not for resale."; MedWatch reporting to FDA and the states involved; an FDA cleared syringe as the only device; documented oral bioavailability for oral forms; and a patient specific prescription. Each peptide is limited to set forms and routes, for example Semax free base intranasal only.
- 503A pharmacies compounding or asked to compound any of the six peptides.
- Telehealth and wellness programs prescribing them.
- Research use only peptide sellers, whose supply the policy aims to displace.
Federal enforcement only, and only for state licensed 503A pharmacies, federal facilities and licensed physicians. It does not cover 503B outsourcing facilities, does not add any peptide to the 503A bulks list, and does not displace state law or state board positions on peptides.
| Source published | October 30, 2026 | Federal Register notice of availability, FR Doc. 2026-22192; filed October 28. |
|---|---|---|
| Effective | October 30, 2026 | HHS states it does not intend to take enforcement action while the 503A bulks list is developed through rulemaking. |
| Comment deadline | November 13, 2026 | The notice allows written comments for 2 weeks after publication on docket HHS-OASH-2026-0496. |
| Expires | Not stated | Runs until each peptide is addressed in a final 503A bulks list rule; HHS may revisit it if a safety signal or quality issue arises. |
This is the first federal opening for compounded peptides, and it is narrow. Outside the six substances, their routes or any one condition, nothing changes, and HHS can revisit it at any time. State notices barring research grade peptides still stand. A pharmacy relying on the policy should be able to show every condition was met for every lot.
- Compare each peptide product you make or list against the six substances and their permitted forms and routes; withdraw anything outside them.
- Keep certificates of analysis and manufacturer registration records for every lot; confirm labels and MedWatch reporting.
- Check the peptide position of each state board where you hold a permit before shipping.
Compounding (503A and 503B). The Compounding domain covers which bulk substances a pharmacy compounds, where they come from and how products are labelled. This policy sets federal conditions on all three for six peptides.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability) PrimaryDepartment of Health and Human Services, Office of the Secretary (Federal Register)Retrieved Nov 15, 2026
91 FR 68526, FR Doc. 2026-22192, docket HHS-OASH-2026-0496; dates, two week comment period, revisit and non binding language.
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B PrimaryDepartment of Health and Human ServicesRetrieved Nov 15, 2026
Ten conditions; Appendix A list; Appendix B identities, permitted forms and routes, and the record of FDA drug center recommendations and committee votes.
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee PrimaryU.S. Food and Drug AdministrationRetrieved Sep 22, 2026
Meeting agenda: the seven peptides considered for the 503A bulks list. Vote outcomes are taken from the HHS policy, not from this page.
Know where your pharmacy stands before the rules change again.
Certified pharmacies are re-verified nightly against state boards, federal enforcement records and their own websites.